These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 32446195)

  • 1. Interactions of recommended COVID-19 drugs with commonly used psychotropics.
    Chatterjee SS; Malathesh BC; Das S; Singh OP
    Asian J Psychiatr; 2020 Aug; 52():102173. PubMed ID: 32446195
    [No Abstract]   [Full Text] [Related]  

  • 2. [Challenges for psychotropics in the context of the SARS-Cov-2 pandemic].
    Javelot H; Llorca PM; Meyer G; Fossati P; Haffen E
    Encephale; 2020 Jun; 46(3S):S116-S118. PubMed ID: 32360037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Informations on psychotropics and their adaptations for patients suffering from mental disorders in France during the SARS-CoV-2 epidemic].
    Javelot H; Llorca PM; Drapier D; Fakra E; Hingray C; Meyer G; Dizet S; Egron A; Straczek C; Roser M; Masson M; Gaillard R; Fossati P; Haffen E
    Encephale; 2020 Jun; 46(3S):S14-S34. PubMed ID: 32376004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Psychopharmacology of COVID-19.
    Bilbul M; Paparone P; Kim AM; Mutalik S; Ernst CL
    Psychosomatics; 2020; 61(5):411-427. PubMed ID: 32425246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of potential therapeutic agents on QT interval in patients with COVID-19 Infection: The importance of close monitoring and correction of electrolytes.
    Habibzadeh P; Moghadami M; Lankarani KB
    Med Hypotheses; 2020 Oct; 143():109847. PubMed ID: 32460209
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment concerns for psychiatric symptoms in patients with COVID-19 with or without psychiatric disorders.
    Zhang K; Zhou X; Liu H; Hashimoto K
    Br J Psychiatry; 2020 Jul; 217(1):351. PubMed ID: 32270760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Considerations for drug interactions on QTc interval in exploratory COVID-19 treatment.
    Roden DM; Harrington RA; Poppas A; Russo AM
    Heart Rhythm; 2020 Jul; 17(7):e231-e232. PubMed ID: 32302703
    [No Abstract]   [Full Text] [Related]  

  • 8. Anticancer drugs and COVID-19 antiviral treatments in patients with cancer: What can we safely use?
    Gougis P; Fenioux C; Funck-Brentano C; Veyri M; Gligorov J; Solas C; Spano JP
    Eur J Cancer; 2020 Sep; 136():1-3. PubMed ID: 32610172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COVID-19 and hydroxychloroquine: Is the wonder drug failing?
    Paliani U; Cardona A
    Eur J Intern Med; 2020 Aug; 78():1-3. PubMed ID: 32553587
    [No Abstract]   [Full Text] [Related]  

  • 10. Guidance on Minimizing Risk of Drug-Induced Ventricular Arrhythmia During Treatment of COVID-19: A Statement from the Canadian Heart Rhythm Society.
    Sapp JL; Alqarawi W; MacIntyre CJ; Tadros R; Steinberg C; Roberts JD; Laksman Z; Healey JS; Krahn AD
    Can J Cardiol; 2020 Jun; 36(6):948-951. PubMed ID: 32299753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Five severe COVID-19 pneumonia patients treated with triple combination therapy with lopinavir/ritonavir, hydroxychloroquine, and interferon β-1b.
    Hong SI; Ryu BH; Chong YP; Lee S; Kim S; Kim HC; Hong KW; Bae IG; Cho OH
    Int J Antimicrob Agents; 2020 Aug; 56(2):106052. PubMed ID: 32544570
    [No Abstract]   [Full Text] [Related]  

  • 12. Race to find COVID-19 treatments accelerates.
    Kupferschmidt K; Cohen J
    Science; 2020 Mar; 367(6485):1412-1413. PubMed ID: 32217705
    [No Abstract]   [Full Text] [Related]  

  • 13. COVID-19 & antiepileptic drugs: Should we pay attention?
    Fırat O; Yalçın N; Demirkan K
    Seizure; 2020 Aug; 80():240-241. PubMed ID: 32663783
    [No Abstract]   [Full Text] [Related]  

  • 14. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
    Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
    Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psychiatric implications of the use of hydroxychloroquine in COVID-19 patients.
    Rani S; Grover S; Mehra A; Sahoo S
    Indian J Pharmacol; 2020; 52(3):229-231. PubMed ID: 32874009
    [No Abstract]   [Full Text] [Related]  

  • 16. Cutaneous sıde-effects of the potential COVID-19 drugs.
    Türsen Ü; Türsen B; Lotti T
    Dermatol Ther; 2020 Jul; 33(4):e13476. PubMed ID: 32358890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus.
    Costanzo M; De Giglio MAR; Roviello GN
    Curr Med Chem; 2020; 27(27):4536-4541. PubMed ID: 32297571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research.
    Bimonte S; Crispo A; Amore A; Celentano E; Cuomo A; Cascella M
    In Vivo; 2020 Jun; 34(3 Suppl):1597-1602. PubMed ID: 32503817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Recommendations about the Use of Psychotropic Medications during the COVID-19 Pandemic].
    Andrade G; Simões do Couto F; Câmara-Pestana L
    Acta Med Port; 2020 Oct; 33(10):693-702. PubMed ID: 32705981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19).
    Giudicessi JR; Noseworthy PA; Friedman PA; Ackerman MJ
    Mayo Clin Proc; 2020 Jun; 95(6):1213-1221. PubMed ID: 32359771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.